Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL496700 | 0.84 | CA4 (0.38) | CA2CA1CA4 | |
| Trifluoroacetic Acid SCHEMBL29039865 | 0.81 | CA4 (0.36) | CA2CA1CA4 | |
| Trifluoroacetic Acid SCHEMBL9296832 | 0.81 | CA4 (0.36) | CA2CA1CA4 | |
| Trifluoroacetic Acid SCHEMBL28135098 | 0.78 | CA1 (0.38) | CA2CA1CA4 | |
| Trifluoroacetic Acid SCHEMBL11639909 | 0.78 | CA4 (0.35) | CA2CA4 | |
| Trifluoroacetic Acid SCHEMBL4528375 | 0.77 | CA4 (0.38) | CA2CA1CA4 | |
| Trifluoroacetic Acid SCHEMBL20541013 | 0.77 | CA4 (0.38) | CA2CA1CA4 | |
| Trifluoroacetic Acid SCHEMBL282294 | 0.77 | — | — | |
| Trifluoroacetic Acid SCHEMBL20569660 | 0.77 | CA4 (0.38) | CA2CA1CA4 | |
| Trifluoroacetic Acid SCHEMBL20571141 | 0.77 | CA4 (0.38) | CA2CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165421-A1 | 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11-BETA-YL]BENZALDEHYDE (E)-OXIME (ASOPRISNIL) | Bayer Pharma AG (DE) | 2013-06-27 | — | — | US | claimed |
| US-8324412-B2 | Method for preparing 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil) | Bayer Pharma AG (DE) | 2012-12-04 | — | — | US | claimed |
| US-20110257142-A1 | METHOD FOR PREPARING 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11-BETA-YL]BENZALDEHYDE (E)-OXIME (ASOPRISNIL) | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-10-20 | — | — | US | claimed |
| CN-101466724-A | Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyde-(E)-oxime (Asoprisnil) | BAYER SCHERING PHARMA AG (DE) | 2009-06-24 | — | — | CN | claimed |
| US-20090054387-A1 | Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-26 | — | — | US | claimed |
| EP-2010555-A2 | METHOD FOR PREPARING 4-[17BETA -METHOXY-17 -ALPHA METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11BETA -YL]BENZALDEHYDE (E)-OXIME (ASOPRISNIL) | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007118717-A2 | METHOD FOR PREPARING 4-[17β-METHOXY-17α-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11β-YL]BENZALDEHYDE (E)-OXIME (ASOPRISNIL) | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-25 | — | — | WO | claimed |
| US-20130165421-A1 | 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11-BETA-YL]BENZALDEHYDE (E)-OXIME (ASOPRISNIL) | Bayer Pharma AG (DE) | 2013-06-27 | — | — | US | disclosed |
| US-8324412-B2 | Method for preparing 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil) | Bayer Pharma AG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20110257142-A1 | METHOD FOR PREPARING 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11-BETA-YL]BENZALDEHYDE (E)-OXIME (ASOPRISNIL) | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20090054387-A1 | Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil) | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-26 | — | — | US | disclosed |
| EP-2010555-A2 | METHOD FOR PREPARING 4-[17BETA -METHOXY-17 -ALPHA METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11BETA -YL]BENZALDEHYDE (E)-OXIME (ASOPRISNIL) | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007118717-A2 | METHOD FOR PREPARING 4-[17β-METHOXY-17α-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11β-YL]BENZALDEHYDE (E)-OXIME (ASOPRISNIL) | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054387-A1 | Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil) | CYP19A1, CYP2C19, CYP17A1 | CA2 3189/4885CA1 2924/4885CA4 1562/4885 |
| US-20130165421-A1 | 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11-BETA-YL]BENZALDEHYDE (E)-OXIME (ASOPRISNIL) | CYP19A1, CYP2C19, CYP17A1 | CA2 3203/4885CA1 3440/4885CA4 1889/4885 |
| US-20110257142-A1 | METHOD FOR PREPARING 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11-BETA-YL]BENZALDEHYDE (E)-OXIME (ASOPRISNIL) | CYP19A1, CYP2C19, CYP17A1 | CA2 3602/4885CA1 3709/4885CA4 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.